Author

Stephen Page

Stephen Page

Writer on DMT, ayahuasca, iboga and tryptamine research. LLB; incoming MSc in Psychedelics: Mind, Medicine and Culture, University of Exeter (2026)

Why 0.4 mg/kg: Strassman's dose-finding logic and its thirty-year hold

ARDMT Field Notes

Why 0.4 mg/kg: Strassman's dose-finding logic and its thirty-year hold

Strassman's dose-finding study, published in Archives of General Psychiatry in 1994, employed a double-blind design with four intravenous dose levels — 0.05, 0.1, 0.2, and 0.4 mg/kg of DMT fumarate

May 27, 2026 · 4 min read

Deuterating DMT: how two neutrons reshape a pharmacokinetic profile

ARDMT Field Notes

Deuterating DMT: how two neutrons reshape a pharmacokinetic profile

When Cybin Inc. filed its patent family around CYB003 — later redesignated SPL028 — the core chemical manoeuvre was, on its face, almost comically modest.

May 26, 2026 · 4 min read

The Bell, the Clog, and the Gallows

Books

The Bell, the Clog, and the Gallows

The Mischievous Dog, taken across its full transmission, turns out to be less a stable moral tale than a record of successive interpretive needs. Each translator alters the object around the dog's neck

May 25, 2026 · 17 min read

Which Ayahuasca?

Cabinet of Marginalia

Which Ayahuasca?

Ayahuasca is not one thing: one name, many brews, hidden variables, and a global habit of flattening complexity into a single word.

May 25, 2026

Shulgin's tryptamine notebooks: the cartography DMT research still navigates by

ARDMT Field Notes

Shulgin's tryptamine notebooks: the cartography DMT research still navigates by

The relevance of Shulgin's tryptamine work to present-day DMT research is not merely historical. Several active lines of enquiry trace their intellectual ancestry directly to his structure-activity observations.

May 25, 2026 · 4 min read

Speech biomarkers after 5-MeO-DMT: can how you talk reveal what changed?

ARDMT Field Notes

Speech biomarkers after 5-MeO-DMT: can how you talk reveal what changed?

Kuc, McAlpine, Sellers, Blackburne, Lametti, and Skipper, writing in the Journal of Psychopharmacology, report on what they term "speech markers of psychological change"

May 24, 2026 · 3 min read

Ayahuasca is not one thing

Pillar

Ayahuasca is not one thing

yahuasca' denotes a variable ethnobotanical category, not a single brew. The variation matters for ceremony, chemistry, consent, and clinical research.

May 24, 2026 · 28 min read

Machine learning validates indigenous folk taxonomy of the ayahuasca vine

ARDMT Field Notes

Machine learning validates indigenous folk taxonomy of the ayahuasca vine

A machine learning study quietly validates indigenous taxonomy of Banisteriopsis caapi — and raises a harder question about what counts as scientific knowledge.

May 23, 2026 · 6 min read

The Trouble with Supernormal Stimuli.

Cabinet of Marginalia

The Trouble with Supernormal Stimuli.

Wide vintage-style ARDMT Field Notes comic strip titled “The Trouble with Supernormal Stimuli,” showing male Australian jewel beetles mistaking glossy brown beer bottles for females, illustrating how exaggerated artificial cues can override natural mating signals and create an evolutionary trap.

May 22, 2026

The Case of the Vanishing Molecule

Cabinet of Marginalia

The Case of the Vanishing Molecule

Wide vintage-style ARDMT Field Notes comic strip titled “The Case of the Vanishing Molecule,” showing the scientific history of endogenous DMT from Julius Axelrod’s 1961 INMT enzyme discovery through inconsistent transmethylation-era findings, Borjigin’s rat brain studies, and modern

May 22, 2026

The Compound That Forgot to be Interesting.

Cabinet of Marginalia

The Compound That Forgot to be Interesting.

The Compound That Forgot to Be Interesting — a field note on timing, context, and rejected purchase orders. In 1931 the Canadian chemist Richard H. F. Manske first synthesised N,N-dimethyltryptamine and entered it into a table of tryptamine derivatives without ever suspecting what it would become.

May 22, 2026

Endogenous DMT from Axelrod to Borjigin: what sixty years have settled and what they have not

ARDMT Field Notes

Endogenous DMT from Axelrod to Borjigin: what sixty years have settled and what they have not

The story begins, as so many stories in psychedelic pharmacology do, with Julius Axelrod. In 1961, working at the National Institute of Mental Health, Axelrod demonstrated that rabbit lung tissue contained an enzyme capable of methylating tryptamine to form DMT.

May 22, 2026 · 4 min read

← Return to homepage